Express Mail No.: EL685694236US

Date: 6 July 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Attorney Docket No.: ARTM 1000-5

RICHARD EUSTIS FULTON III and
WILLIAM R. DUBRUL
Examiner: Unassigned

Application No.: Unassigned Group: Unassigned

Title: BIOPSY LOCALIZATION METHOD AND

DEVICE

BOX PATENT APPLICATION Assistant Commissioner for Patents Washington, D.C. 20231

Filed: Concurrently Herewith

PRELIMINARY AMENDMENT

Dear Sir:

Before the first action in this case, please amend this application as follows. Marked up copies of the amendments to the specification can be found in the attached Appendix.

In The Specification

Page 1, cancel the paragraph at lines 4-9 and substitute the following.

This application is a continuation of application No. 09/366,360 filed June 18, 1999, which application claims the benefit of the following Provisional patent applications. Biopsy Localization Device, Application No. 60/090,243, filed June 22, 1998; Biopsy Localization and Hemostasis Device, Application No. 60/092,734, filed July 14, 1998; Device and Method of Biopsy Localization and Hemostasis, Application No. 60/114,863, filed January 6, 1999; and Device and Method of Biopsy Localization, Hemostasis & Cancer Therapy, Application No. 60/117,421, filed January 27, 1999.

In The Claims

1

2

3

4

5

6 7

1

2

1

2

3

1

2

1

2

3

1

2

1

2

3

1

2

1

2

1

2

1

2

Please cancel Claims 1-52 and add Claims 53-88 as follows.

53.	A biopsy localization device comprising:
	a bioabsorbable element in a pre-delivery state prior to its delivery to a
soft tissue bio	psy site of a patient; and

said bioabsorbable element being of a material which is in a post-delivery state at the biopsy site, the bioabsorbable element being at least one of palpably harder than or remotely visualizable within the surrounding soft tissue at the biopsy site when in the postdelivery state.

- The device according to claim 53 wherein the bioabsorbable element has a 54. hardness of at least about 1.5 times as hard as breast tissue in the post-delivery state.
- The device according to claim 53 wherein the bioabsorbable element swells 55. about 50 to 1500 percent from the pre-delivery state to the post delivery state when placed in contact with an aqueous liquid.
- The device according to claim 53 wherein the bioabsorbable element has a 56. longest dimension of at least about 0.5cm when in the post-delivery state.
- The device according to claim 53 wherein the bioabsorbable element 57. comprises a therapeutic agent, the therapeutic agent comprising at least a chosen one of a chemotherapy agent, a radiation agent and a gene therapy agent.
- The device according to claim 53 wherein the bioabsorbable element 58. comprises reservoir means for subsequently receiving a therapeutic agent.
- The device according to claim 58 wherein the reservoir means comprises reservoir means for receiving at least one of a radiation agent, a gene therapy agent and a chemotherapy agent.
- The device according to claim 53 wherein the bioabsorbable element 60. comprises a bioabsorbable filament.
- The device according to claim 53 further comprising a marker element in 61. contact with the bioabsorbable element.
- The device according to claim 61 wherein the marker element is a radiopaque 62. marker element located generally centrally within the bioabsorbable element.
- The device according to claim the 62 wherein the radiopaque marker element 63. is a chosen one of a permanent marker element and a temporary marker element.

1	64.	The device according to claim 33 wherein the bloadsorbable element has	
2	margins, said	margins being roughened so to help prevent migration of the bioabsorbable	
3	element within soft tissue of a patient.		
1	65.	The device according to claim 64 wherein the bioabsorbable element has	
2	filaments extending from the margins.		
1	66.	The device according to claim 65 wherein the filaments are of same material	
2	as the bioabs	orbable element.	
1	67.	The device according to claim 53 wherein the bioabsorbable element is	
2	remotely vis	ualizable in its post-delivery state by at least one of ultrasound, mammography	
3	and MRI.		
1	68.	The device according to claim 53 wherein the bioabsorbable element is softer	
2	in its post-delivery state than in its pre-delivery state.		
1	69.	A medical device comprising a locatable bioabsorbable element configured for	
2	positioning at a biopsy site at the time of taking a tissue sample from the biopsy site.		
1	70.	A biopsy localization method comprising:	
2		taking a tissue sample from a biopsy site within a patient;	
3		positioning a bioabsorbable element at the biopsy site;	
4		testing the tissue sample; and	
5		if the testing indicates a need to do so relocating the biopsy site by finding the	
6	bioabsorbable element by at least one of the following:		
7		palpation of the patient to feel the bioabsorbable element;	
8		locating inflammation at the biopsy site caused by the bioabsorbable	
9	element;		
10		following a bioabsorbable thread, the thread extending from the	
11	patient's skin to the bioabsorbable element; and		
12		remotely visualizing the bioabsorbable element.	
1	71.	The method according to claim 70 wherein the positioning step is carried out	
2	using said bioabsorbable element and a radiopaque marker.		
1	72.	The device according to claim the 71 wherein the radiopaque marker element	
2	is a chosen of	one of a permanent marker element and a temporary marker element.	
1	73.	The method according to claim 70 wherein the remotely visualizing step is	

carried out to by at least one of ultrasound, mammography and MRI.

1	74.	The method according to claim 70 further comprising the step of selecting the	
2	bioabsorbable element so that after positioning at the target site, the bioabsorbable element		
3	has a hardnes	ss of at lease about 1.5 times as hard as the surrounding tissue.	
1	75.	The method according to claim 74 further comprising the step of effectively	
2	preventing bl	ood from contacting the bioabsorbable element until the bioabsorbable element	
3	is positioned	at the target site, the effectively preventing step being carried out by using a	
4	hemostatic b	ioabsorbable element having a non-hemostatic biodegradable outer layer.	
1	76.	The method according the claim 71 further comprising the step of placing a	
2	marker element at a generally central location within the bioabsorbable element.		
1	77.	A medical treatment method comprising:	
2		taking a tissue sample from a biopsy site within a patient;	
3		positioning a bioabsorbable element at the biopsy site at the time of the taking	
4	of the tissue sample;		
5		testing the tissue sample;	
6		if the testing indicates a need to do so, medically treating the biopsy site.	
1	78.	The method according to claim 77 wherein the medically treating step is	
2	carried out by at least one of:		
3		injecting a radiation-emitting element at the vicinity of the target site;	
4		externally irradiating the target site;	
5		providing a triggering substance to the agent; and	
6		removing additional tissue at the target site.	
1	79.	The method according to claim 77 wherein the medically treating step	
2	comprises delivering a therapeutic agent to the target site.		
1	80.	The method according to claim 79 wherein the delivering step is carried out	
2	using at least one of:		
3		a chemotherapy agent;	
4		a radiation-emitting element;	
5		thermal energy;	
6		ionization energy;	
7		gene therapy;	
8		vector therapy;	
9		electrical therapy;	
10		vibrational therapy; and	
11		anti-angiogenesis.	

1

2

1

2

1

2

1

2

1

2

1

2

3

4

1

2

1 2

3

5

- 81. The method according to claim 77 further comprising relocating the biopsy site by finding the bioabsorbable element.
- 82. The method according to claim 81 wherein the relocating step is carried out by a chosen one of palpation and remote visualization.
- 83. The method according to claim 81 wherein the relocating step is carried out by remote visualization using at least one of ultrasound, mammography and MRI.
- 84. The method according to claim 81 wherein the relocating step is carried out prior to the medically treating step.
- 85. The method according to claim 84 wherein the medical treating step comprises removal of tissue.
- 86. The method according to claim 77 wherein the positioning step is carried out using a remotely visulizable bioabsorable element, and wherein the relocating step comprises guiding a treatment device to the bioabsorable element by at least one of remote visualization and palpation.
- 87. The method according to claim 77 wherein the medically treating step comprises activating the site locatable by the bioabsorbable element.
- 88. The method according to claim 87 wherein the activating step is carried out by at least one of:

injecting a radiation-emitting element at the vicinity of the target site; externally irradiating the target site; and triggering a substance carried by the element.

REMARKS

Claims 53-88 remain in this case.

If the Examiner believes a telephone conversation would aid the prosecution of this case in any way, please call the undersigned at (650) 712-0340.

Respectfully submitted,

Dated: 6 July, 2001.

James F. Hann, Reg. No. 29,719

HAYNES & BEFFEL LLP

P.O. Box 366

Half Moon Bay, California 94019

Phone: 650-712-0340 Fax: 650-712-0263

APPENDIX

The following is a marked up copy of the amended paragraph at lines 4-9 from page 1 of the specification.

This <u>application is a continuation of application No. 09/366,360 filed June 18, 1999,</u> which application claims the benefit of the following Provisional patent applications. Biopsy Localization Device, Application No. 60/090,243, filed June 22, 1998; Biopsy Localization and Hemostasis Device, Application No. 60/092,734, filed July 14, 1998; Device and Method of Biopsy Localization and Hemostasis, Application No. 60/114,863, filed January 6, 1999; and Device and Method of Biopsy Localization, Hemostasis & Cancer Therapy, Application No. 60/117,421, filed January [25] 27, 1999.